Prof. Kenu said in his report report dated 02/12/2022:
“I wish to inform you of the successful recruitment of the first (1st) case at the Kekele Polyclinic yesterday and patient consented to participate in the study and being managed per the study protocol.”
The trial is a double-blind study which means that we do not know if they were given a placebo or our AD-1005, a novel antidiarrheal investigational drug, for Phase II clinical trial with the Pan African Clinical Trials Registry for treatment of severe diarrhea of cholera. nevertheless, our best wishes go to the patient and the family.
This is a momentous milestone with about four months from the start of 2022 rainy season and 299 patents more patients needed to conclude the study.
